2Lucon AM, Pereira MAA, Mendonca BB, et al. Pheochromocytoma: Study of 50 cases.J Urol, 1997, 157 (4): 1208-1212.
3Dubois LA, Gray DK. Dopamine-secreting pheochromocytomas: in search of a syndrome. World J Surg, 2005, 29(7): 909-913.
4Zelinka T, Widimsky J, Weisserova J. Diminished circadian blood pressure rhythm in patients with asymptomatic norrnotensive pheochromocytoma. Physiol Res, 2001; 50(6): 631-634.
5van der Harst E, de Herder WW, de Krijger RR, et al. The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur J Endocrinol, 2002, 147(1): 85-94.
6Motta-Ramirez GA, Remer EM, Herts BR, et al. Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas. Am J Roentgenol, 2005, 185(3): 684-688.
7Eisenhofer G, Keiser HR, Friberg P, et al. Plasma metanephrines are markers of phaeochromocytomaproduced by catechol-O- methyltransferase within tumours. ] Clin Endocrinol Metab, 1998, 83(6): 2175-2185.
8Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. J Clin Endocrinol Metab, 2000, 85(2): 637-644.
9Proye C, Fossati P, Fontaine P, et al. Dopamine-secreting pheochromocytoma: an unrecognized entity? Classification of pheochromocytomas according to their type of secretion. Surgery, 1986, 100(6): 1154-1162.
10Gerlo EAM, Sevens C. Urinary and plasma catecholamines and urinary catecholamine metabolites in phaeochromocytoma: diagnostic value in 19 cases. Clin Chem, 1994, 40(2): 250-256.
